Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemical and Pharmacological Characterization

Danielle Gully, Michel Geslin, Laurence Serva, Evelyne Fontaine, Pierre Roger, Christine Lair, Valerie Darre, Claudine Marcy, Pierre-Eric Rouby, Jacques Simiand, Josette Guitard, Georgette Gout, Regis Steinberg, Daniel Rodier, Guy Griebel, Philippe Soubrie, Marc Pascal, Rebecca Pruss, Bernard Scatton, Jean-Pierre Maffrand and Gerard Le Fur
Journal of Pharmacology and Experimental Therapeutics April 2002, 301 (1) 322-332; DOI: https://doi.org/10.1124/jpet.301.1.322
Danielle Gully
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Geslin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence Serva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelyne Fontaine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Roger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Lair
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valerie Darre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudine Marcy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Eric Rouby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Simiand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josette Guitard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgette Gout
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regis Steinberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Rodier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Griebel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Soubrie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Pascal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Pruss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Scatton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Maffrand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Le Fur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1- (3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a new 2-aminothiazole derivative, shows nanomolar affinity for human cloned or native corticotrophin-releasing factor (CRF)1 receptors (pKivalues of 8.73 and 9.08, respectively), and a 1000-fold selectivity for CRF1 versus CRF2α receptor and CRF binding protein. SSR125543A antagonizes CRF-induced stimulation of cAMP synthesis in human retinoblastoma Y 79 cells (IC50 = 3.0 ± 0.4 nM) and adrenocorticotropin hormone (ACTH) secretion in mouse pituitary tumor AtT-20 cells. SSR125543A is devoid of agonist activity in these models. Its brain penetration was demonstrated in rats by using an ex vivo [125I-Tyr0] ovine CRF binding assay. SSR125543A displaced radioligand binding to the CRF1 receptor in the brain with an ID50 of 6.5 mg/kg p.o. (duration of action >24 h). SSR125543A also inhibited the increase in plasma ACTH levels elicited in rats by i.v. CRF (4 μg/kg) injection (ID50 = 1, 5, or 5 mg/kg i.v., i.p., and p.o., respectively); this effect lasted for more than 6 h when the drug was given orally at a dose of 30 mg/kg. SSR125543A (10 mg/kg p.o.) reduced by 73% the increase in plasma ACTH levels elicited by a 15-min restraint stress in rats. Moreover, SSR125543A (20 mg/kg i.p.) also antagonized the increase of hippocampal acetylcholine release induced by i.c.v. injection of 1 μg of CRF in rats. Finally, SSR125543A reduced forepaw treading induced by i.c.v. injection of 1 μg of CRF in gerbils (ID50 = ∼10 mg/kg p.o.). Altogether, these data indicate that SSR125543A is a potent, selective, and orally active CRF1 receptor antagonist.

Footnotes

  • Abbreviations:
    CRF
    corticotropin-releasing factor
    ACTH
    adrenocorticotropin hormone
    HPA
    hypothalomo-pituitary-adrenal axis
    CRF-BP
    corticotropin-releasing factor-binding protein
    DMSO
    dimethyl sulfoxide
    CHO
    Chinese hamster ovary
    PBS
    phosphate-buffered saline
    ANOVA
    analysis of variance
    ACh
    acetylcholine
    R-121919
    3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine
    antalarmin
    butylethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine
    • Received October 11, 2001.
    • Accepted December 31, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 301 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 301, Issue 1
1 Apr 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemic…
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemical and Pharmacological Characterization

Danielle Gully, Michel Geslin, Laurence Serva, Evelyne Fontaine, Pierre Roger, Christine Lair, Valerie Darre, Claudine Marcy, Pierre-Eric Rouby, Jacques Simiand, Josette Guitard, Georgette Gout, Regis Steinberg, Daniel Rodier, Guy Griebel, Philippe Soubrie, Marc Pascal, Rebecca Pruss, Bernard Scatton, Jean-Pierre Maffrand and Gerard Le Fur
Journal of Pharmacology and Experimental Therapeutics April 1, 2002, 301 (1) 322-332; DOI: https://doi.org/10.1124/jpet.301.1.322

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemical and Pharmacological Characterization

Danielle Gully, Michel Geslin, Laurence Serva, Evelyne Fontaine, Pierre Roger, Christine Lair, Valerie Darre, Claudine Marcy, Pierre-Eric Rouby, Jacques Simiand, Josette Guitard, Georgette Gout, Regis Steinberg, Daniel Rodier, Guy Griebel, Philippe Soubrie, Marc Pascal, Rebecca Pruss, Bernard Scatton, Jean-Pierre Maffrand and Gerard Le Fur
Journal of Pharmacology and Experimental Therapeutics April 1, 2002, 301 (1) 322-332; DOI: https://doi.org/10.1124/jpet.301.1.322
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Iclepertin (BI 425809) in schizophrenia-related models
  • D1 agonist vs. methylphenidate on PFC working memory
  • Obesity Thwarts Preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics